Download PDF
Thromb Haemost
DOI: 10.1055/a-2330-1371
Stroke, Systemic or Venous Thromboembolism

Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis

Danielle Carole Roy 
1   Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
,
Tzu-Fei Wang
1   Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
2   Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
3   The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
,
Ronda Lun
2   Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
3   The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
4   Vascular Neurology, Stanford Healthcare, Palo Alto, California, United States
,
Amin Zahrai
1   Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
3   The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
,
Ranjeeta Mallick
3   The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
,
Dylan Burger
2   Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
3   The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
,
Gabriele Zitikyte
5   Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
,
Steven Hawken   *
1   Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
3   The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
,
Philip Wells   *
1   Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
2   Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
3   The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
› Author Affiliations
› Further Information
    Permissions and Reprints


Abstract

Background Cancer patients have an increased risk of venous thromboembolism (VTE). Currently, the availability of highly discriminatory prediction models for VTE in cancer patients is limited. The implementation of biomarkers in prediction models might lead to refined VTE risk prediction. In this systematic review and meta-analysis, we aimed to evaluate candidate biomarkers and their association with cancer-associated VTE.

Methods We searched Medline, EMBASE, and Cochrane Central for studies that evaluated biomarkers in adult cancer patients from inception to September 2022. We included studies reporting on VTE after a cancer diagnosis with biomarker measurements performed at a defined time point. Median/mean differences (for continuous measures) and odds ratios (for dichotomous measures) with 95% confidence intervals were estimated and pooled using random-effects models.

Results We included 113 studies in the systematic review. Of these, 50 studies were included in the meta-analysis. We identified two biomarkers at cancer diagnosis (factor VIII and time to peak thrombin), three biomarkers pre-chemotherapy (D-dimer, fibrinogen, and mean platelet volume), and one biomarker preoperatively (platelet count) that had significant median or mean differences. Additionally, we found that hemoglobin <100 g/L and white blood count >11 × 109/L were significantly associated with future VTE risk only when measured at cancer diagnosis. Pre-chemotherapy neutrophil-to-lymphocyte ratio ≥3 and preoperative platelet count ≥400 × 109/L were also found to be associated with future VTE risk.

Conclusion In conclusion, this study identified nine candidate blood biomarkers that may help in optimizing VTE prediction in cancer patients that should be further explored in future studies.

Keywords

venous thromboembolism - biomarkers - cancer - systematic review - meta-analysis

Data Availability Statement

Corresponding author for the article has access to all the data and takes responsibility for the analyses conducted as part of this study.


Authors' Contribution

D.C.R., T.-F.W., R.M., and P.W. designed the research question. D.C.R., T.-F.W., A.Z., R.M., and P.W. designed the eligibility criteria and the screening strategy. D.C.R., T.-F.W., R.L., A.Z., R.M., P.W., and S.H. came up with the data extraction items. D.C.R., T.-F.W., A.Z., R.M., and P.W. developed the data synthesis strategy. D.C.R., T.-F.W., A.Z., R.M., and P.W. drafted the protocol manuscript, and it was reviewed and approved by all authors. D.C.R. and R.L. extracted the data. D.C.R., R.M., G.Z., and S.H. aided with data analysis. D.C.R. and G.Z. completed the ROB assessments. D.C.R., T.-F.W., R.M., D.B., S.H., and P.W. interpreted the results. All authors reviewed the results, proofread and approved the final version of the manuscript.


* These authors are co-senior authors.


Supplementary Material



Publication History

Received: 18 October 2023

Accepted: 19 May 2024

Accepted Manuscript online:
20 May 2024

Article published online:
12 June 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
    CrossrefPubMedGoogle Scholar
  • 2 Kyriazi V, Theodoulou E. Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch Pathol Lab Med 2013; 137 (09) 1286-1295
    CrossrefPubMedGoogle Scholar
  • 3 Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res 2018; 164 (Suppl. 01) S112-S118
    CrossrefPubMedGoogle Scholar
  • 4 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
    CrossrefPubMedGoogle Scholar
  • 5 Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res 2016; 137: 3-10
    CrossrefPubMedGoogle Scholar
  • 6 Arshad N, Bjøri E, Hindberg K, Isaksen T, Hansen JB, Braekkan SK. Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost 2017; 15 (02) 295-303
    CrossrefPubMedGoogle Scholar
  • 7 Mandalà M, Reni M, Cascinu S. et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007; 18 (10) 1660-1665
    CrossrefPubMedGoogle Scholar
  • 8 Carrier M, Abou-Nassar K, Mallick R. et al; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380 (08) 711-719
    CrossrefPubMedGoogle Scholar
  • 9 Bosch FTM, Mulder FI, Kamphuisen PW. et al. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Adv 2020; 4 (20) 5215-5225
    CrossrefPubMedGoogle Scholar
  • 10 Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2016; 12 (12) CD008500
    PubMedGoogle Scholar
  • 11 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
    CrossrefPubMedGoogle Scholar
  • 12 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
    CrossrefPubMedGoogle Scholar
  • 13 Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G. Update on guidelines for the management of cancer-associated thrombosis. Oncologist 2021; 26 (01) e24-e40
    CrossrefPubMedGoogle Scholar
  • 14 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedGoogle Scholar
  • 15 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7 (03) 291-292
    CrossrefPubMedGoogle Scholar
  • 16 Pelzer U, Sinn M, Stieler J, Riess H. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? [in German]. Dtsch Med Wochenschr 2013; 138 (41) 2084-2088
    PubMedGoogle Scholar
  • 17 Cella CA, Di Minno G, Carlomagno C. et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist 2017; 22 (05) 601-608
    CrossrefPubMedGoogle Scholar
  • 18 Pabinger I, van Es N, Heinze G. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018; 5 (07) e289-e298
    CrossrefPubMedGoogle Scholar
  • 19 van Es N, Di Nisio M, Cesarman G. et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 2017; 102 (09) 1494-1501
    CrossrefPubMedGoogle Scholar
  • 20 Moik F, Englisch C, Pabinger I, Ay C. Risk assessment models of cancer-associated thrombosis - potentials and perspectives. Thromb Update 2021; 5: 100075
    CrossrefPubMedGoogle Scholar
  • 21 Ferroni P, Riondino S, Formica V. et al. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. Int J Cancer 2015; 136 (05) 1234-1240
    CrossrefPubMedGoogle Scholar
  • 22 Kuderer NM, Poniewierski MS, Culakova E. et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a global prospective study (CANTARISK). Oncologist 2018; 23 (02) 247-255
    CrossrefPubMedGoogle Scholar
  • 23 Moher D, Shamseer L, Clarke M. et al; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4 (01) 1
    CrossrefPubMedGoogle Scholar
  • 24 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 2021; 18 (03) e1003583
    CrossrefPubMedGoogle Scholar
  • 25 Definition of biomarker - NCI Dictionary of Cancer Terms - NCI. Published February 2, 2011. Accessed 1 March 2024 at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker
    PubMedGoogle Scholar
  • 26 McGrath S, Sohn H, Steele R, Benedetti A. Meta-analysis of the difference of medians. Biom J 2020; 62 (01) 69-98
    CrossrefPubMedGoogle Scholar
  • 27 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (03) 177-188
    CrossrefPubMedGoogle Scholar
  • 28 McGrath S, Sohn H, Steele R, Benedetti A. Two-sample aggregate data meta-analysis of medians. Biom J 2020; 62 (01) 69-98
    CrossrefPubMedGoogle Scholar
  • 29 Cai S, Zhou J, Pan J. Estimating the sample mean and standard deviation from order statistics and sample size in meta-analysis. Stat Methods Med Res 2021; 30 (12) 2701-2719
    CrossrefPubMedGoogle Scholar
  • 30 Granholm A, Alhazzani W, Møller MH. Use of the GRADE approach in systematic reviews and guidelines. Br J Anaesth 2019; 123 (05) 554-559
    CrossrefPubMedGoogle Scholar
  • 31 McGrath S, Zhao X, Katzenschlager S, Ozturk O, Steele R, Benedetti A. Metamedian: Meta-analysis of Medians. Published online 2023. Accessed 24 May 2024 at: https://CRAN.R-project.org/package=metamedian
    PubMedGoogle Scholar
  • 32 Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019; 22 (04) 153-160
    CrossrefPubMedGoogle Scholar
  • 33 Kaida S, Miyake T, Murata S. et al. A prospective multicenter observational study of venous thromboembolism after gastric cancer surgery (SHISA-1601). Eur Surg Res 2021; 62 (01) 10-17
    CrossrefPubMedGoogle Scholar
  • 34 Chen Y, Wang Y, Xie S. et al. A risk of venous thromboembolism algorithm as a predictor of venous thromboembolism in patients with colorectal cancer. Clin Appl Thromb Hemost 2021 ;27:10760296211064900
    PubMedGoogle Scholar
  • 35 Norris LA, Ward MP, O'Toole SA. et al. A risk score for prediction of venous thromboembolism in gynecologic cancer: the Thrombogyn score. Res Pract Thromb Haemost 2020; 4 (05) 848-859
    CrossrefPubMedGoogle Scholar
  • 36 Li D, Pise MN, Overman MJ. et al. ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. Cancer Med 2015; 4 (11) 1651-1658
    CrossrefPubMedGoogle Scholar
  • 37 Mandalà M, Barni S, Prins M. et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010; 21 (04) 871-876
    CrossrefPubMedGoogle Scholar
  • 38 Pépin M, Kleinjan A, Hajage D. et al. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost 2016; 14 (02) 306-315
    CrossrefPubMedGoogle Scholar
  • 39 Tabernero J, Hozak RR, Yoshino T. et al. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol 2018; 29 (03) 602-609
    CrossrefPubMedGoogle Scholar
  • 40 von Tempelhoff GF, Nieman F, Heilmann L, Hommel G. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy. Clin Hemorheol Microcirc 2000; 22 (02) 107-130
    PubMedGoogle Scholar
  • 41 Königsbrügge O, Posch F, Riedl J. et al. Association between decreased serum albumin with risk of venous thromboembolism and mortality in cancer patients. Oncologist 2016; 21 (02) 252-257
    CrossrefPubMedGoogle Scholar
  • 42 Moeini A, Machida H, Takiuchi T. et al. Association of nonalcoholic fatty liver disease and venous thromboembolism in women with endometrial cancer. Clin Appl Thromb Hemost 2017; 23 (08) 1018-1027
    CrossrefPubMedGoogle Scholar
  • 43 Grilz E, Posch F, Königsbrügge O. et al. Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer. Thromb Haemost 2018; 118 (11) 1875-1884
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Almasi M, Sevcikova S, Slaby O. et al. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. Clin Lymphoma Myeloma Leuk 2011; 11 (05) 414-420
    CrossrefPubMedGoogle Scholar
  • 45 Khorana AA, Barnard J, Wun T. et al. Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI. Blood Adv 2022; 6 (04) 1212-1221
    CrossrefPubMedGoogle Scholar
  • 46 Faille D, Bourrienne MC, de Raucourt E. et al. Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget 2018; 9 (41) 26453-26465
    CrossrefPubMedGoogle Scholar
  • 47 Thaler J, Ay C, Kaider A. et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro-oncol 2014; 16 (12) 1645-1651
    CrossrefPubMedGoogle Scholar
  • 48 von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77 (03) 456-461
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 von Tempelhoff GF, Niemann F, Schneider DM, Kirkpatrick CJ, Hommel G, Heilmann L. Blood rheology during chemotherapy in patients with ovarian cancer. Thromb Res 1998; 90 (02) 73-82
    CrossrefPubMedGoogle Scholar
  • 50 López-Salazar J, Ramírez-Tirado LA, Gómez-Contreras N. et al. Cancer-associated prothrombotic pathways: leucocytosis, but not thrombocytosis, correlates with venous thromboembolism in women with ovarian cancer. Intern Med J 2020; 50 (03) 366-370
    CrossrefPubMedGoogle Scholar
  • 51 Liang H, Guo X, Li Y. Cervical cancer associated biomarkers of identify high risk of venous thrombosis. Clin Lab 2020; 66 (05) 771-777
    PubMedGoogle Scholar
  • 52 Bharthuar A, Khorana AA, Hutson A. et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 2013; 132 (02) 180-184
    CrossrefPubMedGoogle Scholar
  • 53 Mauracher L-M, Posch F, Martinod K. et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J Thromb Haemost 2018; 16 (03) 508-518
    CrossrefPubMedGoogle Scholar
  • 54 Yang Y, Zhou Z, Niu XM. et al. Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients. J Surg Oncol 2012; 106 (06) 736-741
    CrossrefPubMedGoogle Scholar
  • 55 Bagratuni T, Kastritis E, Politou M. et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol 2013; 88 (09) 765-770
    CrossrefPubMedGoogle Scholar
  • 56 Guadagni F, Riondino S, Formica V. et al. Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer. World J Gastroenterol 2017; 23 (28) 5187-5195
    CrossrefPubMedGoogle Scholar
  • 57 Gezelius E, Flou Kristensen A, Bendahl PO. et al. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: a sub-study of RASTEN - a randomized trial with low molecular weight heparin. PLoS One 2018; 13 (11) e0207387
    CrossrefPubMedGoogle Scholar
  • 58 Dranichnikov P, Mahteme H, Cashin PH, Graf W. Coagulopathy and venous thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2021; 28 (12) 7772-7782
    CrossrefPubMedGoogle Scholar
  • 59 Cui LN, Li N, Fu S, Zhang X, Wang X, Wang RT. Combination of preoperative D-dimer and mean platelet volume predicts postoperative deep venous thrombosis in breast cancer patients. Cancer Biomark 2018; 21 (04) 909-913
    CrossrefPubMedGoogle Scholar
  • 60 Huang Y, Ding H, Luo M. et al. Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma. Support Care Cancer 2022; 30 (07) 6063-6069
    CrossrefPubMedGoogle Scholar
  • 61 Ay C, Vormittag R, Dunkler D. et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27 (25) 4124-4129
    CrossrefPubMedGoogle Scholar
  • 62 Arpaia G, Carpenedo M, Verga M. et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis 2009; 20 (03) 170-175
    CrossrefPubMedGoogle Scholar
  • 63 Kodama J, Seki N, Masahiro S. et al. D-dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecologic cancer. Ann Oncol 2010; 21 (08) 1651-1656
    CrossrefPubMedGoogle Scholar
  • 64 Riedl J, Kaider A, Marosi C. et al. Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis. Thromb Haemost 2017; 117 (01) 90-98
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Li J, Yi J, Hua L. et al. Development and validation of a predictive score for venous thromboembolism in newly diagnosed non-small cell lung cancer. Thromb Res 2021; 208: 45-51
    CrossrefPubMedGoogle Scholar
  • 66 Li J, Qiang WM, Wang Y, Wang XY. Development and validation of a risk assessment nomogram for venous thromboembolism associated with hospitalized postoperative Chinese breast cancer patients. J Adv Nurs 2021; 77 (01) 473-483
    CrossrefPubMedGoogle Scholar
  • 67 Posch F, Riedl J, Reitter EM. et al. Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: a prospective study. J Thromb Haemost 2020; 18 (06) 1348-1356
    CrossrefPubMedGoogle Scholar
  • 68 Ferroni P, Martini F, Portarena I. et al. Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients–a pilot study. Support Care Cancer 2012; 20 (11) 2713-2720
    CrossrefPubMedGoogle Scholar
  • 69 Ay C, Posch F, Kaider A, Zielinski C, Pabinger I. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. J Thromb Haemost 2015; 13 (03) 390-397
    CrossrefPubMedGoogle Scholar
  • 70 Jianlong M, Diansheng Z, Jing R. Estimation of venous thromboembolism risk with thrombotic biomarkers in cancer patients [in Chinese]. Zhonghua Zhong Liu Za Zhi 2015; 37 (04) 283-289
    PubMedGoogle Scholar
  • 71 Schorling RM, Pfrepper C, Golombek T. et al. Evaluation of biomarkers for the prediction of venous thromboembolism in ambulatory cancer patients. Oncol Res Treat 2020; 43 (09) 414-427
    CrossrefPubMedGoogle Scholar
  • 72 Ferroni P, Guadagni F, Riondino S. et al. Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. Haematologica 2014; 99 (10) 1638-1644
    CrossrefPubMedGoogle Scholar
  • 73 Rupa-Matysek J, Lembicz M, Rogowska EK, Gil L, Komarnicki M, Batura-Gabryel H. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. Med Oncol 2018; 35 (05) 63
    CrossrefPubMedGoogle Scholar
  • 74 Wu X, Xue X, Tang J. et al. Evaluation of risk factors for venous thromboembolism in Chinese women with epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23 (01) 65-72
    CrossrefPubMedGoogle Scholar
  • 75 Sanfilippo KM, Carson KR, Wang TF. et al. Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma. Res Pract Thromb Haemost 2022; 6 (01) e12634
    CrossrefPubMedGoogle Scholar
  • 76 Rupa-Matysek J, Brzeźniakiewicz-Janus K, Gil L, Krasiński Z, Komarnicki M. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med 2018; 7 (07) 2868-2875
    CrossrefPubMedGoogle Scholar
  • 77 Posch F, Hofer S, Thaler J. et al. Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Transl Res 2020; 215: 41-56
    CrossrefPubMedGoogle Scholar
  • 78 Roy DC, Wang TF, Mallick R. et al. Growth differentiation factor-15, high-sensitivity cardiac troponin T, and N-terminal pro-B-type natriuretic peptide for predicting risk of venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2022; 122 (07) 1169-1176
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Vormittag R, Simanek R, Ay C. et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29 (12) 2176-2181
    CrossrefPubMedGoogle Scholar
  • 80 Ay C, Simanek R, Vormittag R. et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112 (07) 2703-2708
    CrossrefPubMedGoogle Scholar
  • 81 Simanek R, Vormittag R, Ay C. et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8 (01) 114-120
    CrossrefPubMedGoogle Scholar
  • 82 Posch F, Riedl J, Reitter EM. et al. Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A Multi-State Model. Thromb Haemost 2016; 115 (04) 817-826
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Otasevic V, Mihaljevic B, Milic N. et al. Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J 2022; 20 (01) 20
    CrossrefPubMedGoogle Scholar
  • 84 Zhou Q, Zhu C, Shen Z. et al. Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period. Eur J Surg Oncol 2020; 46 (05) 855-861
    CrossrefPubMedGoogle Scholar
  • 85 Park K, Ryoo BY, Ryu MH. et al. Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: a prospective study. World J Gastrointest Oncol 2017; 9 (04) 176-183
    CrossrefPubMedGoogle Scholar
  • 86 Shi S, Cheng J, Zhao Y, Chen W. Incidence, and preoperative and intraoperative prognostic factors of deep venous thrombosis in patients with glioma following craniotomy. Clin Neurol Neurosurg 2021; 210: 106998
    CrossrefPubMedGoogle Scholar
  • 87 Kruger S, Haas M, Burkl C. et al. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - a retrospective cohort study. Thromb Res 2017; 157: 9-15
    CrossrefPubMedGoogle Scholar
  • 88 Khan S, Kelly KJ, Veerapong J, Lowy AM, Baumgartner JM. Incidence, risk factors, and prevention strategies for venous thromboembolism after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2019; 26 (07) 2276-2284
    CrossrefPubMedGoogle Scholar
  • 89 Reitter EM, Ay C, Kaider A. et al. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients. Clin Exp Immunol 2014; 177 (01) 253-260
    CrossrefPubMedGoogle Scholar
  • 90 Kirwan CC, McCollum CN, McDowell G, Byrne GJ. Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis. Clin Appl Thromb Hemost 2015; 21 (05) 420-427
    CrossrefPubMedGoogle Scholar
  • 91 Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010; 126 (02) 113-118
    CrossrefPubMedGoogle Scholar
  • 92 Fotiou D, Sergentanis TN, Papageorgiou L. et al. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J 2018; 8 (11) 102
    CrossrefPubMedGoogle Scholar
  • 93 Mir Seyed Nazari P, Marosi C, Moik F. et al. Low systemic levels of chemokine C-C motif ligand 3 (CCL3) are associated with a high risk of venous thromboembolism in patients with glioma. Cancers (Basel) 2019; 11 (12) 2020
    CrossrefPubMedGoogle Scholar
  • 94 Streetly M, Hunt BJ, Parmar K, Jones R, Zeldis J, Schey S. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 2005; 74 (04) 293-296
    CrossrefPubMedGoogle Scholar
  • 95 Thaler J, Ay C, Mackman N. et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10 (07) 1363-1370
    CrossrefPubMedGoogle Scholar
  • 96 Oto J, Plana E, Solmoirago MJ. et al. microRNAs and markers of neutrophil activation as predictors of early incidental post-surgical pulmonary embolism in patients with intracranial tumors. Cancers (Basel) 2020; 12 (06) 1536
    CrossrefPubMedGoogle Scholar
  • 97 Oto J, Navarro S, Larsen AC. et al. MicroRNAs and neutrophil activation markers predict venous thrombosis in pancreatic ductal adenocarcinoma and distal extrahepatic cholangiocarcinoma. Int J Mol Sci 2020; 21 (03) 840
    CrossrefPubMedGoogle Scholar
  • 98 Rojnuckarin P, Uaprasert N, Sriuranpong V. Monocyte count associated with subsequent symptomatic venous thromboembolism (VTE) in hospitalized patients with solid tumors. Thromb Res 2012; 130 (06) e279-e282
    CrossrefPubMedGoogle Scholar
  • 99 Muñoz Martín AJ, Ortega I, Font C. et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer 2018; 118 (08) 1056-1061
    CrossrefPubMedGoogle Scholar
  • 100 Unruh D, Schwarze SR, Khoury L. et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol 2016; 132 (06) 917-930
    CrossrefPubMedGoogle Scholar
  • 101 Wang JK, Boorjian SA, Frank I. et al. Non-O blood type is associated with an increased risk of venous thromboembolism after radical cystectomy. Urology 2014; 83 (01) 140-145
    CrossrefPubMedGoogle Scholar
  • 102 Ferroni P, Martini F, Portarena I. et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer 2012; 13 (06) 482-487
    CrossrefPubMedGoogle Scholar
  • 103 Fuentes HE, Paz LH, Wang Y, Oramas DM, Simons CR, Tafur AJ. Performance of current thromboembolism risk assessment tools in patients with gastric cancer and validity after first treatment. Clin Appl Thromb Hemost 2018; 24 (05) 790-796
    CrossrefPubMedGoogle Scholar
  • 104 Wang Y, Attar BM, Fuentes HE, Yu J, Zhang H, Tafur AJ. Performance of Khorana risk score for prediction of venous thromboembolism in patients with hepatocellular carcinoma. Clin Appl Thromb Hemost 2018; 24 (03) 471-476
    CrossrefPubMedGoogle Scholar
  • 105 Conteduca V, Scarpi E, Wetterskog D. et al. Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. Int J Cancer 2022; 150 (07) 1166-1173
    CrossrefPubMedGoogle Scholar
  • 106 Merkow RP, Bilimoria KY, McCarter MD. et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg 2011; 254 (01) 131-137
    CrossrefPubMedGoogle Scholar
  • 107 Sonaglia F, Agnelli G, Baroni M, Severi P, Quintavalla R, D'Angelo SV. Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery. Blood Coagul Fibrinolysis 1999; 10 (08) 459-463
    CrossrefPubMedGoogle Scholar
  • 108 Zwicker JI, Liebman HA, Bauer KA. et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol 2013; 160 (04) 530-537
    CrossrefPubMedGoogle Scholar
  • 109 Ay C, Dunkler D, Simanek R. et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29 (15) 2099-2103
    CrossrefPubMedGoogle Scholar
  • 110 Chalayer E, Talbot A, Frenzel L. et al. Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: lessons from the substudy of IFM/DFCI 2009 cohort. J Thromb Haemost 2022; 20 (08) 1859-1867
    CrossrefPubMedGoogle Scholar
  • 111 Roselli M, Ferroni P, Portarena I. et al. Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients. Thromb Haemost 2012; 108 (06) 1243-1245
    PubMedGoogle Scholar
  • 112 Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost 2016; 14 (09) 1773-1778
    CrossrefPubMedGoogle Scholar
  • 113 Stender MT, Frøkjaer JB, Larsen TB, Lundbye-Christensen S, Thorlacius-Ussing O. Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum 2009; 52 (03) 446-451
    CrossrefPubMedGoogle Scholar
  • 114 Abu Saadeh F, Langhe R, Galvin DM. et al. Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. Thromb Res 2016; 139: 135-141
    CrossrefPubMedGoogle Scholar
  • 115 Casadei Gardini A, Carloni S, Scarpi E. et al. Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial. Oncotarget 2016; 7 (09) 10193-10202
    CrossrefPubMedGoogle Scholar
  • 116 Hoke M, Dieckmann K, Koppensteiner R, Schillinger M, Marosi C, Mlekusch W. Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme - results from a pilot study. Wien Klin Wochenschr 2011; 123 (7-8): 199-203
    CrossrefPubMedGoogle Scholar
  • 117 Syrigos K, Grapsa D, Sangare R. et al. Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer-associated thrombosis: the observational ROADMAP-CAT study. Oncologist 2018; 23 (11) 1372-1381
    CrossrefPubMedGoogle Scholar
  • 118 Tafur AJ, Dale G, Cherry M. et al. Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. Thromb Res 2015; 136 (06) 1120-1125
    CrossrefPubMedGoogle Scholar
  • 119 Sinnamon AJ, Tong JKC, Bailey EA. et al. Prospective implementation of a standardized screening protocol for deep venous thrombosis in abdominal surgical oncology patients. J Surg Oncol 2018; 118 (03) 568-573
    CrossrefPubMedGoogle Scholar
  • 120 Lee E, Kang SB, Choi SI. et al. Prospective study on the incidence of postoperative venous thromboembolism in Korean patients with colorectal cancer. Cancer Res Treat 2016; 48 (03) 978-989
    CrossrefPubMedGoogle Scholar
  • 121 Dickmann B, Ahlbrecht J, Ay C. et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013; 98 (08) 1309-1314
    CrossrefPubMedGoogle Scholar
  • 122 Iversen LH, Thorlacius-Ussing O. Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 2002; 87 (03) 402-408
    Article in Thieme ConnectPubMedGoogle Scholar
  • 123 Kuk A, Magnowska M, Suchy W. et al. Retrospective evaluation of thromboembolism risk in ovarian cancer patients treated with bevacizumab. Target Oncol 2017; 12 (04) 495-503
    CrossrefPubMedGoogle Scholar
  • 124 Yu I, Chen L, Ruan JY, Chang JT, Cheung WY. Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients. Support Care Cancer 2016; 24 (03) 1199-1208
    CrossrefPubMedGoogle Scholar
  • 125 Boone BA, Zenati MS, Rieser C. et al. Risk of venous thromboembolism for patients with pancreatic ductal adenocarcinoma undergoing preoperative chemotherapy followed by surgical resection. Ann Surg Oncol 2019; 26 (05) 1503-1511
    CrossrefPubMedGoogle Scholar
  • 126 Poruk KE, Firpo MA, Huerter LM. et al. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010; 19 (10) 2605-2610
    CrossrefPubMedGoogle Scholar
  • 127 Matsuo K, Ross MS, Im DD. et al. Significance of venous thromboembolism in women with uterine carcinosarcoma. Gynecol Oncol 2018; 148 (02) 267-274
    CrossrefPubMedGoogle Scholar
  • 128 Posch F, Thaler J, Zlabinger GJ. et al. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study (CATS). Clin Cancer Res 2016; 22 (01) 200-206
    CrossrefPubMedGoogle Scholar
  • 129 Cini M, Zamagni E, Valdré L. et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol 2010; 84 (06) 484-492
    CrossrefPubMedGoogle Scholar
  • 130 Kovacs MJ, Davies GA, Chapman JAW. et al. Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. Br J Haematol 2015; 168 (04) 511-517
    CrossrefPubMedGoogle Scholar
  • 131 Wang J, Hu B, Li T. et al. The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism. Ann Transl Med 2019; 7 (23) 724-724
    CrossrefPubMedGoogle Scholar
  • 132 Rink M, Riethdorf S, Yu H. et al. The impact of circulating tumor cells on venous thromboembolism and cardiovascular events in bladder cancer patients treated with radical cystectomy. J Clin Med 2020; 9 (11) 3478
    CrossrefPubMedGoogle Scholar
  • 133 Kusunoki M, Miyake K, Shindo T. et al. The incidence of deep vein thrombosis in Japanese patients undergoing endoscopic submucosal dissection. Gastrointest Endosc 2011; 74 (04) 798-804
    CrossrefPubMedGoogle Scholar
  • 134 Piketty AC, Fléchon A, Laplanche A. et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 2005; 93 (08) 909-914
    CrossrefPubMedGoogle Scholar
  • 135 Albertin CL, Uppal S, Al-Niaimi AN, Seo S, Hinshaw JL, Hartenbach EM. Thrombocytosis is predictive of postoperative pulmonary embolism in patients with gynecologic cancer. Int J Gynecol Cancer 2015; 25 (06) 1096-1101
    CrossrefPubMedGoogle Scholar
  • 136 Von Tempelhoff GF, Heilmann L. Thrombosis and Hemorheology in Patients with Breast Cancer and Adjuvant Chemotherapy. Clin Hemorheol 1995; 15 (03) 311-323
    PubMedGoogle Scholar
  • 137 Kanz R, Vukovich T, Vormittag R. et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011; 9 (01) 57-63
    CrossrefPubMedGoogle Scholar
  • 138 Ahlbrecht J, Dickmann B, Ay C. et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2012; 30 (31) 3870-3875
    CrossrefPubMedGoogle Scholar
  • 139 Kitayama H, Kondo T, Sugiyama J. et al. Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study. BMC Cancer 2017; 17 (01) 351
    CrossrefPubMedGoogle Scholar
  • 140 Tham T, Rahman L, Persaud C, Olson C, Costantino P. Venous thromboembolism risk in head and neck cancer: significance of the preoperative platelet-to-lymphocyte ratio. Otolaryngol Head Neck Surg 2018; 159 (01) 85-91
    CrossrefPubMedGoogle Scholar
  • 141 Matsuo K, Hasegawa K, Yoshino K. et al. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer 2015; 51 (14) 1978-1988
    CrossrefPubMedGoogle Scholar
  • 142 Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth 2014; 58 (05) 515-523
    CrossrefPubMedGoogle Scholar
  • 143 Mutlu H, Artış TA, Erden A, Akca Z. Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis. Clin Appl Thromb Hemost 2013; 19 (03) 331-333
    CrossrefPubMedGoogle Scholar
  • 144 Lippi G, Buonocore R, Cervellin G. The mean platelet volume is decreased in patients diagnosed with venous thromboembolism in the emergency department. Semin Thromb Hemost 2016; 42 (06) 632-635
    Article in Thieme ConnectPubMedGoogle Scholar
  • 145 Kondo S, Sasaki M, Hosoi H. et al. Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma. Oncotarget 2018; 9 (24) 16883-16890
    CrossrefPubMedGoogle Scholar
  • 146 Malaponte G, Signorelli SS, Bevelacqua V. et al. Increased levels of NF-kB-Dependent markers in cancer-associated deep venous thrombosis. PLoS One 2015; 10 (07) e0132496
    CrossrefPubMedGoogle Scholar
  • 147 Park MS, Spears GM, Bailey KR. et al. Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: a prospective cohort study. J Trauma Acute Care Surg 2017; 83 (03) 381-387
    CrossrefPubMedGoogle Scholar
  • 148 Wang Z, Chen X, Wu J. et al. Low mean platelet volume is associated with deep vein thrombosis in older patients with hip fracture. Clin Appl Thromb Hemost 2022 ;28:10760296221078837
    PubMedGoogle Scholar
  • 149 Hansen ES, Edvardsen MS, Aukrust P. et al. Combined effect of high factor VIII levels and high mean platelet volume on the risk of future incident venous thromboembolism. J Thromb Haemost 2023; 21 (10) 2844-2853
    CrossrefPubMedGoogle Scholar
  • 150 Evensen LH, Folsom AR, Pankow JS. et al. Hemostatic factors, inflammatory markers, and risk of incident venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost 2021; 19 (07) 1718-1728
    CrossrefPubMedGoogle Scholar
  • 151 Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms–the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71 (06) 719-722
    Article in Thieme ConnectPubMedGoogle Scholar
  • 152 Ay C, Dunkler D, Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
    CrossrefPubMedGoogle Scholar
  • 153 Mulder FI, Candeloro M, Kamphuisen PW. et al; CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica 2019; 104 (06) 1277-1287
    CrossrefPubMedGoogle Scholar
  • 154 van Es N, Ventresca M, Di Nisio M. et al; IPDMA Heparin Use in Cancer Patients Research Group. The Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis. J Thromb Haemost 2020; 18 (08) 1940-1951
    CrossrefPubMedGoogle Scholar
  • 155 Naggara O, Raymond J, Guilbert F, Roy D, Weill A, Altman DG. Analysis by categorizing or dichotomizing continuous variables is inadvisable: an example from the natural history of unruptured aneurysms. AJNR Am J Neuroradiol 2011; 32 (03) 437-440
    CrossrefPubMedGoogle Scholar
  • 156 Eggemann H, Ehricke J, Ignatov T. et al. Platelet count after chemotherapy is a predictor for outcome for ovarian cancer patients. Cancer Invest 2015; 33 (05) 193-196
    CrossrefPubMedGoogle Scholar
  • 157 Nurgalieva Z, Liu CC, Du XL. Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer. Med Oncol 2011; 28 (03) 716-725
    CrossrefPubMedGoogle Scholar
  • 158 Săftescu S, Popovici D, Oprean C. et al. Endurance of erythrocyte series in chemotherapy. Exp Ther Med 2020; 20 (06) 214
    CrossrefPubMedGoogle Scholar
  • 159 Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. Thromb Haemost 2015; 113 (06) 1176-1183
    Article in Thieme ConnectPubMedGoogle Scholar
  • 160 Malte AL, Højbjerg JA, Larsen JB. Platelet parameters as biomarkers for thrombosis risk in cancer: a systematic review and meta-analysis. Semin Thromb Hemost 2024; 50 (03) 360-383
    Article in Thieme ConnectPubMedGoogle Scholar
  • 161 Ten Berg MJ, van den Bemt PMLA, Shantakumar S. et al. Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study. Drug Saf 2011; 34 (12) 1151-1160
    CrossrefPubMedGoogle Scholar